Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Clover Starts Fifth Clinical Trial of TRAIL-Trimer Fusion Candidate

publication date: Nov 21, 2019

Clover Biopharma, a Chengdu global clinical-stage biotech, has dosed the first patient in an Australian Phase I trial of SCB-313 in cancer patients with malignant pleural effusions (MPE). SCB-313, a fully-human TRAIL-Trimer fusion protein, is being tested in five clinical studies in China and Australia. The trials are enrolling patients in three oncology indications -- malignant ascites, peritoneal carcinomatosis, and malignant pleural effusions. MPE is the abnormal accumulation of fluid in the pleural cavity in cancer patients, especially from lung cancer, indicating the presence of cancer cells in the cavity. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital